Form 4: Atossa Therapeutics Director Chen Shu-Chih Acquires Stock Options

Director Chen Shu-Chih of Atossa Therapeutics acquires stock options exercisable for 125,000 shares of common stock.

Summary

• On June 27, 2024, Chen Shu-Chih, a director of Atossa Therapeutics, acquired stock options.
• The options are exercisable for 125,000 shares of Atossa Therapeutics common stock.
• The exercise price of the options is $1.05 per share.
• The options vest on a quarterly basis over 12 months following June 27, 2024, contingent upon continued service.
• The options expire on June 27, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects a director's increased stake in the company.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the options.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in publicly traded companies to incentivize and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry to align their interests with shareholders.
• The vesting schedule of 12 months is fairly standard.
• The exercise price being set at the closing price on the day prior to the grant is also a common practice.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates